In patients with cirrhosis, portal hypertension is frequently complicated by hyponatremia — most commonly of hypervolemic origin. When first-line measures fail to restore serum sodium, a structured escalation protocol applies.
Hyponatremia in a patient with cirrhosis, most commonly hypervolemic. Hypervolemia is the most common cause of hyponatremia in patients with cirrhosis.
Initial management — including diuretic cessation, free water restriction, human albumin solution, and correction of hypokalemia — did not achieve its goal: correction of hyponatremia (increase in serum sodium). This protocol addresses that failure.
The next step involves pharmacological agents targeted at correcting hyponatremia. The approach includes a vaptan-class option for appropriate patients. The full structured regimen — including specific agents, selection criteria, and clinical conditions — is available through the protocol below.
DOI: 10.1016/j.jceh.2022.03.002
Hypervolemia is the most common cause of hyponatremia in patients with cirrhosis.
Midodrine and vaptans are beneficial in treating hyponatremia.
Tolvaptan is more effective in treating hyponatremia and is preferred for patients with refractory hyponatremia in grade 3 ascites for a short duration.
View source ↗